Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

This study tests whether adding an immunotherapy drug (triprizumab, an anti-PD-1 antibody) to radiation therapy before surgery improves outcomes for people with early-stage non-small cell lung cancer (NSCLC). Giving treatment before surgery is called neoadjuvant therapy. **You may be eligible if...** - You are 18–70 years old - You have confirmed resectable (operable) stage IIA–IIIA non-small cell lung cancer - You have not had any prior treatment for this cancer - You have at least one measurable tumor - Your general health and organ function are adequate (good performance status and blood/lab values) **You may NOT be eligible if...** - Your cancer is at a more advanced or earlier stage - You have already received treatment for this cancer - Your health or organ function doesn't meet the minimum requirements Talk to your doctor to see if this trial is right for you.